Table 3. Total number, median and ranges of assessed histological and immunostained pulmonary arteries.
Study /Group | Horses (n) | Histology | Immunostaining | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Arteries (total) | Median/ horse | Range | Arteries (total) | Median/ horse | Range | ||||||
Study 1 | |||||||||||
Controls | 6 | 222 | 37 | 19–51 | - | - | - | ||||
Asthma | 12 | 502 | 36 | 27–68 | - | - | - | ||||
• Remission | 6 | 272 | 43 | 31–66 | |||||||
• Exacerbation | 6 | 230 | 33 | 27–68 | |||||||
Study 2 | |||||||||||
Controls | 5 | 93 | 15 | 10–32 | 111 | 22 | 14–32 | ||||
Asthma | 6 | 116 | 17 | 7–44 | 114 | 17 | 8–33 | ||||
Study 3 | |||||||||||
Antigen avoidance | |||||||||||
• Baseline | 5 (4)a | 58 | 7 | 2–26 | 73a | 15a | 11–32a | ||||
• Follow up | 5 (4)a | 126 | 26 | 4–42 | 51a | 13a | 6–19a | ||||
Corticosteroids | |||||||||||
• Baseline | 6 | 46 | 8 | 4–12 | 74 | 12 | 4–23 | ||||
• Follow up | 6 | 123 | 18 | 13–36 | 97 | 14 | 6–32 |
aIn study 3, one horse of the antigen avoidance group was not considered for the statistical analysis of the pulmonary arteries smooth muscle mass quantification because at the baseline only one immunostained artery was measurable.